AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
169.00
+3.74 (2.26%)
Nov 6, 2025, 11:32 AM EST
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
58.13B
Revenue Growth
+13.52%
P/S Ratio
4.33
Revenue / Employee
616.41K
Employees
94,300
Market Cap
251.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 221.55M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 2.61M |
AstraZeneca News
- 4 hours ago - UK will only be able to afford generic drugs if NHS fails to pay more, says AstraZeneca boss - The Guardian
- 5 hours ago - AstraZeneca's 9M and Q3 2025 Financial Results - Business Wire
- 5 hours ago - AstraZeneca (AZN) Reports Q3 Revenue as Company Eyes Growth with Phase III Trials - GuruFocus
- 5 hours ago - AstraZeneca Stuns Wall Street With Surprise Profit Surge - GuruFocus
- 6 hours ago - AstraZeneca (AZN) Surpasses Q3 Expectations with Strong Oncology Sales - GuruFocus
- 7 hours ago - AstraZeneca (AZN) Exceeds Expectations and Confirms 2025 Outlook - GuruFocus
- 7 hours ago - AstraZeneca beats Q3 estimates on oncology strength - Seeking Alpha
- 8 hours ago - AstraZeneca (AZN) Surpasses Q3 Earnings and Revenue Expectations - GuruFocus